| The
anti-depression drug Zoloft® improves the moods of Alzheimer's patients, but
not their cognitive abilities such as thinking, remembering and learning, according
to a study reported in the July 2003 issue of the Archives of General Psychiatry.
Zoloft (sertraline
hydrochloride) is a common treatment for psychiatric diseases
such as major depression, obsessive compulsive disorder and panic
disorder. About 25 percent of Alzheimer's patients suffer from
depression.
When
combined with the cognitive impairment of Alzheimer's, major depression is extremely
disabling and can lead to death or suicide, according to study author Dr. Constantine
Lyketsos, professor of psychiatry and behavioral sciences at Johns Hopkins. However,
Lyketsos said the depression in Alzheimer's patients often goes undiagnosed in
part because doctors feel they have little to offer in the form of treatment.
"This study shows that a simple treatment for depression improves the
quality of life and seems to slow the functional decline of Alzheimer's disease,"
said Lyketsos. "This simple and safe treatment for depression has tremendous
potential for improving the quality of life for both Alzheimer's patients and
their caregivers." The
study involved 44 patients suffering from Alzheimer's disease and major depression
who either received a placebo or Zoloft once a day for 12 weeks. The participants
and their caregivers were also educated about the illnesses and received encouragement
and emotional support throughout the study.
The researchers
found that 84 percent of those receiving Zoloft were positively
influenced, versus 35 percent in the placebo group. Treating depression
was accompanied by fewer behavioral disturbances and improved
activities of daily living.
Based
on the results, Lyketsos and his team are leading a clinical trial to investigate
the long-term benefits of Zoloft for Alzheimer's patients and determine how well
the treatment eases the burden of caregivers. Other
sources: Johns Hopkins Medical Institutions |